2,8-dimethoxy-11H-indolo[3,2-c]quinoline | 710944-43-7

• 英文名称: 2,8-dimethoxy-11H-indolo[3,2-c]quinoline
• CAS: 710944-43-7
• 化学式: C₁₇H₁₄N₂O₂
• 分子量: 278.31
• InChiKey: VROKBFHTRLGPDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.89
• 重原子数：
  21.0
• 可旋转键数：
  2.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  47.14
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  2,8-dimethoxy-11H-indolo[3,2-c]quinoline 在 氢溴酸 、 potassium carbonate 作用下， 以 甲醇 、 氯仿 、 水 、 溶剂黄146 为溶剂， 反应 48.0h， 生成 2-[[2-[2-(dimethylamino)ethoxy]-11H-indolo[3,2-c]quinolin-8-yl]oxy]-N,N-dimethylethanamine
  参考文献：
  名称：

  Design of antineoplastic agents based on the '2-phenylnaphthalene-type' structural pattern—synthesis and biological activity studies of 11H-indolo[3.2-c]quinoline derivatives

  摘要：

  Designed as a new group of planar molecule containing the proposed 2-phenylnaphthalene-type structure, a number of 11H-indolo[3.2-c]quinoline derivatives were synthesized and evaluated biologically. Several compounds were found to possess cytotoxic activity against the growth of human promyclocytic leukemia cells (HL-60), against the small cell lung cancer (SCLC), and showed good response in the National Cancer Institute preclinical antitumor drug discovery 60-cell line panel. (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved.

  DOI：

  10.1016/s0223-5234(02)01420-4
• 作为产物：
  描述：

  6-甲氧基-2,3-二氢喹啉-4-酮 、 (4-甲氧基苯基)肼 在 盐酸 作用下， 以 正丁醇 为溶剂， 反应 20.0h， 以47%的产率得到2,8-dimethoxy-11H-indolo[3,2-c]quinoline
  参考文献：
  名称：

  Design of antineoplastic agents based on the '2-phenylnaphthalene-type' structural pattern—synthesis and biological activity studies of 11H-indolo[3.2-c]quinoline derivatives

  摘要：

  Designed as a new group of planar molecule containing the proposed 2-phenylnaphthalene-type structure, a number of 11H-indolo[3.2-c]quinoline derivatives were synthesized and evaluated biologically. Several compounds were found to possess cytotoxic activity against the growth of human promyclocytic leukemia cells (HL-60), against the small cell lung cancer (SCLC), and showed good response in the National Cancer Institute preclinical antitumor drug discovery 60-cell line panel. (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved.

  DOI：

  10.1016/s0223-5234(02)01420-4